NCT05347212View on ClinicalTrials.gov

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 22, 2022

Primary Completion Date

July 16, 2027

Study Completion Date

July 16, 2027

Conditions

CarcinomasRenal Medullary Carcinoma

Interventions

DRUG

Nivolumab

Given by IV

DRUG

Relatlimab

Given by IV

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER